MS and BTK Inhibitors

Town Hall Meeting with Aaron Boster, MD - Smoldering MS, Disease progression and moreПодробнее

RealTalk MS ECTRIMS Extra: Tolebrutinib and SPMSПодробнее

Will Living with MS be Better in 2025?Подробнее

Recent multiple sclerosis therapeutics-أ.د.عمرو حسن الحسني أستاذ المخ و الأعصابПодробнее

Therapeutic Potential of BTK Inhibitor Tolebrutinib in NonRelapsing Secondary Progressive MSПодробнее

Smoldering MS: The Silent Progression Your Doctor Might MissПодробнее

Conversations on MS with Dr. Andrew Wolf, September 25, 2024Подробнее

MS Progression: Smoldering MS discussion with Dr. Gabriel Pardo - MS ExerciseПодробнее

Promising New Options in MS CareПодробнее

Investigating evobrutinib and other BTK inhibitors for the treatment of MSПодробнее

2023 endMS Conference - Dr. Mark Freedman: Advancements in MS TreatmentsПодробнее

Research Update: Clinical Trials for Multiple SclerosisПодробнее

Potential of BTK Inhibitors for Primary Progressive Multiple SclerosisПодробнее

BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?Подробнее

Multiple Sclerosis RESEARCH BREAKTHROUGH!Подробнее

Addressing the Unmet Needs of Managing MS SymptomsПодробнее

Understanding smoldering pathology in MSПодробнее

Remyelination for MS: Remyelination Clincal Trials & more! - MS ExerciseПодробнее

Challenges and Potential of BTK Inhibitors in MS TreatmentПодробнее

An update on research in BTK inhibitors for the treatment of MSПодробнее